START Taipei is dedicated to the conduct of Phase I Clinical Trials of novel anticancer agents.

The mission of START Taipei, along with our other sites worldwide, is to accelerate the development of new anticancer drugs with the purpose of improving quality of life and survival for patients with cancer.

This International program is the first step in our goal to keep the development of anticancer agents operating 24 hours a day. Because of the work of scientists like those at START and START Madrid, real progress is being made against cancer. Through the hard work of these physicians and the continuing advances in technology we are able to improve the tools to understand, detect, and diagnose cancer. Today, people with cancer are living longer than ever before with a better quality of life.

All START sites share the same Standard Operating Procedures, central budgeting, efficient and proactive IT systems, EMRs, highly specialized organization, as well as an expert and fully dedicated staff.

START Taipei consists of a team of highly trained physicians and staff with extensive experience in Phase I clinical trials research. Our drug development program is not only furthering cancer research, but also offers hope to patients facing the toughest cancer battles.